公开(公告)号：EP0551401B2

公开(公告)日：2004-12-01

申请号：EP91918778.1

申请日：1991-09-12

申请人： THE JOHNS HOPKINS UNIVERSITY ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： FROST, Philip ,  VOGELSTEIN, Bert ,  CHERNAJOVSKY, Yuti ,  FEARON, Eric, R. ,  PARDOLL, Drew

IPC分类号： C12N15/85 ,  A61K48/00 ,  A61K35/12 ,  C12N5/10

CPC分类号： C07K14/005 ,  A61K35/13 ,  A61K39/0011 ,  A61K48/00 ,  C07K14/34 ,  C07K14/55 ,  C07K14/57 ,  C12N2710/16622 ,  C12N2760/16122

摘要： The invention provides a preparation of tumor cell lines containing an exogenous gene encoding a polypeptide that potentiates the immune response to the tumor, for example, interleukin-2. The invention includes methods for cancer therapy by immunization with the immunopotentiating tumor cell. The invention also provides methodology whereby one can selectively ablate in vitro and in vivo genetically altered cells. A preferred embodiment of this aspect of the invention includes a cell containing a first exogenous gene encoding an immunopotentiating polypeptide and a second exogenous gene encoding a "lethal" or "suicide" polypeptide, preferably under the control of an inducible promoter. Introduction of the second exogenous gene confers the ability to selectively kill the tumor cell by inducing a promoter in operative linkage to the gene encoding the lethal polypeptide to initiate transcription of the polypeptide. Diphtheria toxin or the thymidine kinase of Herpes simplex virus are exemplary lethal genes. An exemplary promoter employed is the 6-16 promoter, which is inducible with low levels of interferon. Methods for using the cells in cancer therapy are also provided.

公开(公告)号：EP0551401B1

公开(公告)日：1995-11-02

申请号：EP91918778.1

申请日：1991-09-12

申请人： THE JOHNS HOPKINS UNIVERSITY ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： FROST, Philip ,  VOGELSTEIN, Bert ,  CHERNAJOVSKY, Yuti ,  FEARON, Eric, R. ,  PARDOLL, Drew

IPC分类号： C12N15/85 ,  A61K48/00 ,  A61K35/12 ,  C12N5/10

CPC分类号： C07K14/005 ,  A61K35/13 ,  A61K39/0011 ,  A61K48/00 ,  C07K14/34 ,  C07K14/55 ,  C07K14/57 ,  C12N2710/16622 ,  C12N2760/16122

摘要： The invention provides a preparation of tumor cell lines containing an exogenous gene encoding a polypeptide that potentiates the immune response to the tumor, for example, interleukin-2. The invention includes methods for cancer therapy by immunization with the immunopotentiating tumor cell. The invention also provides methodology whereby one can selectively ablate in vitro and in vivo genetically altered cells. A preferred embodiment of this aspect of the invention includes a cell containing a first exogenous gene encoding an immunopotentiating polypeptide and a second exogenous gene encoding a "lethal" or "suicide" polypeptide, preferably under the control of an inducible promoter. Introduction of the second exogenous gene confers the ability to selectively kill the tumor cell by inducing a promoter in operative linkage to the gene encoding the lethal polypeptide to initiate transcription of the polypeptide. Diphtheria toxin or the thymidine kinase of Herpes simplex virus are exemplary lethal genes. An exemplary promoter employed is the 6-16 promoter, which is inducible with low levels of interferon. Methods for using the cells in cancer therapy are also provided.

公开(公告)号：EP0551401A1

公开(公告)日：1993-07-21

申请号：EP91918778.0

申请日：1991-09-12

申请人： THE JOHNS HOPKINS UNIVERSITY ,  BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM

发明人： FROST, Philip ,  VOGELSTEIN, Bert ,  CHERNAJOVSKY, Yuti ,  FEARON, Eric, R. ,  PARDOLL, Drew

IPC分类号： A61K38 ,  A61K35 ,  A61K39 ,  A61K48 ,  A61P35 ,  A61P37 ,  C07K14 ,  C12N5 ,  C12N15

CPC分类号： C07K14/005 ,  A61K35/13 ,  A61K39/0011 ,  A61K48/00 ,  C07K14/34 ,  C07K14/55 ,  C07K14/57 ,  C12N2710/16622 ,  C12N2760/16122

摘要： The invention provides a preparation of tumor cell lines containing an exogenous gene encoding a polypeptide that potentiates the immune response to the tumor, for example, interleukin-2. The invention includes methods for cancer therapy by immunization with the immunopotentiating tumor cell. The invention also provides methodology whereby one can selectively ablate in vitro and in vivo genetically altered cells. A preferred embodiment of this aspect of the invention includes a cell containing a first exogenous gene encoding an immunopotentiating polypeptide and a second exogenous gene encoding a "lethal" or "suicide" polypeptide, preferably under the control of an inducible promoter. Introduction of the second exogenous gene confers the ability to selectively kill the tumor cell by inducing a promoter in operative linkage to the gene encoding the lethal polypeptide to initiate transcription of the polypeptide. Diphtheria toxin or the thymidine kinase of Herpes simplex virus are exemplary lethal genes. An exemplary promoter employed is the 6-16 promoter, which is inducible with low levels of interferon. Methods for using the cells in cancer therapy are also provided.